The failed promise of the US’s Inflation Reduction Act for patients with diabetes

Five years ago, I wrote an article for The BMJ1 describing the struggles I’ve experienced in trying to afford insulin as a type 1 diabetic patient in the United States. Since my diagnosis in 1996, my unchanged Humalog insulin has increased in list price from $21 a vial (£17.80; €21.07) to $275 or more a vial.2Like most people with type 1 diabetes, I need three or more vials a month to survive. Even with health insurance, I’ve given up seemingly everything to afford this essential medicine: I’ve sold all of my belongings, including my car; moved away from my family; cashed out my retirement account; borrowed money from my retired parents; and even given up my dog, Nicky, because I could no longer afford to keep both of us alive and healthy.With US headlines proclaiming earlier this year that “House passes bill to cap insulin prices”3 and “House passes insulin…
Read Original Article: The failed promise of the US’s Inflation Reduction Act for patients with diabetes »